person · Reporting owner
Fralick Celeste Rachelle
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aspira Women's Health Inc.
Report date March 31, 2025 · Filed April 01, 2025
Section 16 reporting ended · disclosed 2025-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,665 |
Reported balance
After 2025-03-31 transaction · row 1
1 source rowRow 1 · 2025-03-31 · Exercise / conversion · Acquired 5,000 · Balance 55,665 F1: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on March 31, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,000 |
Reported balance
After 2025-03-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-31 · Exercise / conversion · Disposed 5,000 · Balance 5,000 F2: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock. F3: On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on March 31, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.
F2: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.
F3: On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2025 Filed Apr 1, 2025 22:42 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-002185 · ownership.xml · derivative · entry 2 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock. F3 · derivative.exercise_date: On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 22:42 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-002185 · ownership.xml · nonDerivative · entry 1 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on March 31, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024. Read SEC document |
| December 31, 2024 Filed Jan 9, 2025 00:12 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001911051-25-000001 · primary_doc.xml · derivative · entry 2 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock. F3 · derivative.exercise_date: On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on December 31, 2024. The common stock into which such vested RSUs converted on December 31, 2024 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on December 31, 2024. The common stock into which such vested RSUs converted on December 31, 2024 is reported in Table I on this Form 4. Read SEC document |
| December 31, 2024 Filed Jan 9, 2025 00:12 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001911051-25-000001 · primary_doc.xml · nonDerivative · entry 1 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on December 31, 2024. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 21:19 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001911051-24-000001 · primary_doc.xml · derivative · entry 2 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock. F3 · derivative.exercise_date: On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on September 30, 2024. The common stock into which such vested RSUs converted on September 30, 2024 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on September 30, 2024. The common stock into which such vested RSUs converted on September 30, 2024 is reported in Table I on this Form 4. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 21:19 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001911051-24-000001 · primary_doc.xml · nonDerivative · entry 1 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on September 30, 2024. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024. Read SEC document |
| August 22, 2024 Filed Aug 26, 2024 11:16 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-100339 · ownership.xml · derivative · entry 1 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The award will vest in four substantially equal installments on September 30, 2024, December 31, 2024, March 31, 2025 and the date of the annual shareholders' meeting, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: The award will vest in four substantially equal installments on September 30, 2024, December 31, 2024, March 31, 2025 and the date of the annual shareholders' meeting, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 20:23 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantCommon Stock | 15,381 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-096277 · ownership.xml · nonDerivative · entry 1 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,665 F1 · shares: The shares of common stock represent restricted stock units with the contingent right to receive one share of common stock of Aspira Women's Health Inc. for each restricted stock unit. The restricted stock unit vested in full on August 12, 2024. Read SEC document |
| August 28, 2023 Filed Dec 29, 2023 21:09 UTC Amendment | Aspira Women's Health Inc. AWH · Entity 7871 | GrantCommon Stock | 13,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001911051-23-000004 · primary_doc.xml · nonDerivative · entry 1 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,284 F1 · shares: The shares of common stock represent restricted stock units with contingent right to receive one share of common stock. The restricted stock units vest 1/3 on each of June 1, 2023, September 1, 2023 and December 1, 2023. F2 · shares: This report is being filed to correct the grant date of the restricted stock units. Read SEC document |
| July 25, 2023 Filed Jul 26, 2023 23:34 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantCommon Stock | 13,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001911051-23-000003 · primary_doc.xml · nonDerivative · entry 1 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,284 F1 · shares: The shares of common stock represent restricted stock units with contingent right to receive one share of common stock. The restricted stock units vest 1/3 on each of June 1, 2023, September 1, 2023 and December 1, 2023. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 23:28 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | PurchaseCommon Stock | 754 | $3.98 | $3,000.92 |
DisclosureSEC source: 0001911051-23-000002 · primary_doc.xml · nonDerivative · entry 1 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,032 Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 01:32 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantCOMMON STOCK | 66,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001911051-23-000001 · primary_doc.xml · nonDerivative · entry 1 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,199 F1 · shares: The shares of common stock represent restricted stock units with contingent right to receive one share of common stock. The restricted stock units will vest on April 1, 2023. Read SEC document |
| August 25, 2022 Filed Aug 30, 2022 01:57 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | PurchaseWarrant (right to buy) · Derivative | 6,667 | Not disclosed Strike: $0.88 | Not disclosed |
DisclosureSEC source: 0001911051-22-000003 · primary_doc.xml · derivative · entry 2 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common stock, par value $0.001 · 6,667 shares Expires 2027-08-25 F1 · price: Each share of common stock was purchased together with one warrant to purchase one share of common stock (each share and related warrant, a "unit"), at a price of $0.75 per unit. Read SEC document |
| August 25, 2022 Filed Aug 30, 2022 01:57 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | PurchaseCommon Stock | 6,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001911051-22-000003 · primary_doc.xml · nonDerivative · entry 1 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,945 F1 · price: Each share of common stock was purchased together with one warrant to purchase one share of common stock (each share and related warrant, a "unit"), at a price of $0.75 per unit. F2 · balance_after: Total reflects the adjustment of 3,393 shares of common stock previously reported as part of a restricted stock unit grant made on March 31, 2022. Read SEC document |
| March 31, 2022 Filed Apr 5, 2022 00:29 UTC | Aspira Women's Health Inc. awh · Entity 7871 | GrantCommon Stock | 99,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001911051-22-000002 · primary_doc.xml · nonDerivative · entry 1 Fralick Celeste Rachelle · CIK 0001911051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,671 F1 · shares: The restricted stock units will vest in four equal installments on April 1, 2022, June 1, 2022, September 1, 2022 and December 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.